HCA Reports First Quarter 2009 Results(sales of facilities and impairment of lo...),Health

Date:4/27/2009

sales of facilities and impairment of long-lived assets and adjusted EBITDA are not measures of financial performance under accounting principles generally accepted in the United States, and should not be considered as alternatives to net income attributable to HCA Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Inc., excluding losses (gains) on sales of facilities and impairment of long-lived assets and adjusted EBITDA are not measurements determined in accordance with generally accepted accounting principles and are susceptible to varying calculations, net income attributable to HCA Inc., excluding losses (gains) on sales of facilities and impairment of long-lived assets and adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies. HCA Inc. Condensed Consolidated Balance Sheets (Dollars in millions) March 31, December 31, ASSETS 2009 2008 ---- ---- Current assets: Cash and cash equivalents $356 $465 Accounts receivable, less allowance for doubtful accounts 3,870 3,780 Inventories 717 737 Deferred income taxes 988 914 Other 558 405 --- --
'/>"/>

SOURCE HCA Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine news :

1. Recent Study Disproves General Hospitals Ongoing Criticism of Physician Owned Hospitals, Shows Little to No Effect on General Hospitals Business, Reports Physician Hospitals of America
2. Neovasc Inc. Reports Year 2008 Financial Results
3. NBTY Reports Second Quarter Results
4. Statement from USPA Exec. Dir. on News Reports of Florida Pharmacy Admission of Error in the Medicine Dispensed to the Horses Who Died on Sunday
5. Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65.
6. Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results
7. NeoGenomics, Inc. Reports First Quarter 2009 Financial Results
8. Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results
9. CuraGen Reports First Quarter 2009 Financial Results
10. NuVasive Reports First Quarter 2009 Financial Results
11. Torchmark Corporation Reports First Quarter 2009 Results